Why the study?
Does azimilide improve force of contraction and induce vasodilation in rat models of cardiac hypertrophy and failure?
Does azimilide improve force of contraction and induce vasodilation in rat models of cardiac hypertrophy and failure?
Answers are grounded in this paper and cite their sources.
Azimilide acts as a vasodilator and positive inotrope in rat models of heart failure, suggesting it warrants further investigation for heart failure treatment.
We tested whether azimilide has potential for use in the treatment of heart failure. Azimilide, > or =3 x 10(-5) M, had no effect on the quiescent Wistar-Kyoto (WKY) rat aorta, or mesenteric and intralobar pulmonary arteries. Azimilide > or =3 x 10(-5) M relaxed the KCl-contracted aorta and portal vein. Azimilide, 10(-7)-10(-5) M, prolonged the WKY left ventricular action potential and augmented the force of contraction of left ventricle strips from 12- and 22-month-old WKY rats. Spontaneously hypertensive rats (SHRs), at ages 12 and 22 months, are models of cardiac hypertrophy and failure, respectively. The augmentation of force with azimilide was similar on 12- and 22-month-old WKY rats and 12-month-old SHRs but reduced on the 22-month-old SHR left ventricle. Azimilide, 3 x 10(-6) and 10(-5) M, augmented the force responses of the 22-month-old SHR left ventricle by 40 and 50%, respectively. As azimilide is a vasodilator and positive inotrope in the rat, and the positive inotropic effect is present in heart failure, azimilide should undergo further testing as a positive inotrope for the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Nand et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: